OBJECTIVE: We examined perceived consequences/benefits of cigarette smoking and motivation for quitting in nontreatment-seeking smokers who had schizophrenia or schizoaffective disorder (N = 100) or had no Axis I psychiatric disorder (normals, N = 100). METHODS: Participants completed questionnaires and provided a breath carbon monoxide (CO) sample 10-15 minutes after smoking 1 preferred-brand cigarette. Primary assessments included the Smoking Consequences Questionnaire-Adult, the Reasons for Quitting Scale, and the Stages of Change. RESULTS: There were no differences between the schizophrenia and control group in mean age of smoking onset (16.2 ± 5.4 vs 15.6 ± 5.5 y, P = .44), number of cigarettes daily (17.9 ± 11.6 vs 17.0 ± 7.9, P = 0.51), or in breath CO (28.0 ± 14.5 vs 22.9 ± 8.0 ppm, P = .61). Compared with normals, people with schizophrenia report greater stimulation/state enhancement (P < .0001) and social facilitation (P < .004) from smoking. People with schizophrenia had less appreciation of health risks associated with smoking than normal controls (P < .0001) and were less motivated to quit smoking than normal controls (P = .002), even though they were as likely to be in the preparation stage of change. Immediate reinforcement (P = .04) and health concerns (P = .002) were rated lower as motivators for considering quitting smoking in schizophrenia than normals. People with schizophrenia reported greater motivation to stop smoking due to social pressure/rewards than normals (P = .047). CONCLUSIONS: This study underscores the degree to which people with schizophrenia perceive the state-enhancing effects of smoking and their lower appreciation for health risks of smoking compared with normal controls.
OBJECTIVE: We examined perceived consequences/benefits of cigarette smoking and motivation for quitting in nontreatment-seeking smokers who had schizophrenia or schizoaffective disorder (N = 100) or had no Axis I psychiatric disorder (normals, N = 100). METHODS:Participants completed questionnaires and provided a breath carbon monoxide (CO) sample 10-15 minutes after smoking 1 preferred-brand cigarette. Primary assessments included the Smoking Consequences Questionnaire-Adult, the Reasons for Quitting Scale, and the Stages of Change. RESULTS: There were no differences between the schizophrenia and control group in mean age of smoking onset (16.2 ± 5.4 vs 15.6 ± 5.5 y, P = .44), number of cigarettes daily (17.9 ± 11.6 vs 17.0 ± 7.9, P = 0.51), or in breath CO (28.0 ± 14.5 vs 22.9 ± 8.0 ppm, P = .61). Compared with normals, people with schizophrenia report greater stimulation/state enhancement (P < .0001) and social facilitation (P < .004) from smoking. People with schizophrenia had less appreciation of health risks associated with smoking than normal controls (P < .0001) and were less motivated to quit smoking than normal controls (P = .002), even though they were as likely to be in the preparation stage of change. Immediate reinforcement (P = .04) and health concerns (P = .002) were rated lower as motivators for considering quitting smoking in schizophrenia than normals. People with schizophrenia reported greater motivation to stop smoking due to social pressure/rewards than normals (P = .047). CONCLUSIONS: This study underscores the degree to which people with schizophrenia perceive the state-enhancing effects of smoking and their lower appreciation for health risks of smoking compared with normal controls.
Authors: A Herrán; A de Santiago; M Sandoya; M J Fernández; J F Diez-Manrique; J L Vázquez-Barquero Journal: Schizophr Res Date: 2000-01-21 Impact factor: 4.939
Authors: Mark Barnes; Bruce R Lawford; Simon C Burton; Karen R Heslop; Ernest P Noble; Karrin Hausdorf; Ross McD Young Journal: Aust N Z J Psychiatry Date: 2006 Jun-Jul Impact factor: 5.744
Authors: Deanna L Kelly; Robert P McMahon; Heidi J Wehring; Fang Liu; Kristen M Mackowick; Douglas L Boggs; Kimberly R Warren; Stephanie Feldman; Joo-Cheol Shim; Raymond C Love; Lisa Dixon Journal: Schizophr Bull Date: 2009-12-17 Impact factor: 9.306
Authors: William J Kowalczyk; Heidi J Wehring; George Burton; Heather Raley; Stephanie Feldman; Stephen J Heishman; Deanna L Kelly Journal: J Dual Diagn Date: 2016-11-18
Authors: Alana M Rojewski; Stephen Baldassarri; Nina A Cooperman; Ellen R Gritz; Frank T Leone; Megan E Piper; Benjamin A Toll; Graham W Warren Journal: Nicotine Tob Res Date: 2016-01-17 Impact factor: 4.244
Authors: Sun S Kim; Sangkeun Chung; Jong-Il Park; Ae-Ja Jung; David Kalman; Douglas M Ziedonis Journal: Arch Psychiatr Nurs Date: 2013-07-26 Impact factor: 2.218
Authors: Xiang Yang Zhang; Da Chun Chen; Yun Long Tan; Mei Hong Xiu; Jingyi Cui; Li Hui; Fu De Yang; Thomas R Kosten Journal: Psychopharmacology (Berl) Date: 2013-08-21 Impact factor: 4.530